David A. Siegel Galecto, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.68 - $2.84 $7,896 - $13,348	-4,700 Reduced 8.77%	48,900 $123,000
Q1 2023 May 15, 2023	SELL	$1.21 - $2.86 $10,890 - $25,740	-9,000 Reduced 14.38%	53,600 $106,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $58.5 $31,164 - $1.72 Million	-29,400 Reduced 31.96%	62,600 $71,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $60.0 $20,511 - $774,000	-12,900 Reduced 12.3%	92,000 $174,000
Q2 2022 Aug 15, 2022	SELL	$1.22 - $2.74 $47,336 - $106,312	-38,800 Reduced 27.0%	104,900 $181,000
Q1 2022 May 16, 2022	SELL	$1.72 - $3.31 $241,144 - $464,062	-140,200 Reduced 49.38%	143,700 $316,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $3.58 $92,920 - $144,632	40,400 Added 16.59%	283,900 $860,000
Q3 2021 Nov 15, 2021	BUY	$3.59 - $5.0 $874,165 - $1.22 Million	243,500 New	243,500 $874,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $131M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.